Full Press Release Details
Rafael Holdings Reports Second Quarter Fiscal
2024 Financial Results
Company remains focused on generating shareholder
value by advancing portfolio and identifying attractive opportunities for strategic investments
Increased ownership in Day Three Labs to a majority
NEWARK, NJ - March 13, 2024 (GLOBE NEWSWIRE) - Rafael
Holdings, Inc. (NYSE: RFL), today reported its financial results for the second quarter of fiscal 2024 - and the six months ended
"During fiscal 2024, we will continue to
focus on advancing our existing portfolio and intend to leverage our strong balance sheet with selective strategic investments in companies
with the potential to generate value for our stockholders. We are extremely pleased to welcome Dr. John Goldberg to the Rafael team as
our Chief Medical Officer. John is a highly respected senior executive with nearly two decades of experience in drug development. John
will be an integral member of our team, as we advance our existing assets and evaluate additional opportunities for investment,"
said Bill Conkling, CEO of Rafael Holdings. Bill added, "We are encouraged by the positive developments for Cyclo Therapeutics'
(Nasdaq: CYTH) Phase 3 registrational clinical trial for patients with Niemann-Pick Disease Type C and in the increasing momentum behind
Day Three Labs, which reimagines existing cannabis offerings with pharmaceutical-grade technology to bring to market better, cleaner,
more precise and predictable products."
Rafael Holdings, Inc. Second Quarter Fiscal Year 2024 Financial
As of January 31, 2024, we had cash, cash equivalents
and marketable securities of $71.7 million.
For the three months ended January 31, 2024,
we recorded net income from continuing operations of $5.9 million, or $0.25 per fully diluted share versus a net loss from continuing
operations of $3.3 million, or $0.13 per share in the year ago period. The net income reported during the second quarter was driven by
an unrealized gain of $9.7 million on our investments in Cyclo Therapeutics, offset by a loss of $1.6 million on our initial investment
in Day Three Labs. During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest
in the company with 79% of the shares outstanding and began consolidating its financial results in the second quarter of 2024.
For the three months ended January 31, 2024, research and development
expenses were $0.6 million compared to $2.2 million in the year ago period. The year over year reduction is due to the, previously disclosed,
winding down of early-stage programs, including at Barer Institute.
For the three months ended January 31, 2024, general
and administrative expenses from continuing operations were $2.6 million. For the same period in the prior year, general and administrative
expenses were $2.1 million. The increase was primarily related to increases in non-cash stock-based compensation expenses and professional
Rafael Holdings, Inc. First Half Fiscal Year 2024 Financial Results
For the six months ended January 31, 2024, we recorded net income from
continuing operations of $2.1 million, or $0.10 per fully diluted share versus a net loss from continuing operations of $8.5 million,
or $0.36 per share in the year ago period. The net income recorded during the first half of fiscal 2024 was driven by an unrealized gain
of $7.6 million on our investments in Cyclo Therapeutics, offset by a loss of $1.6 million on our initial investment in Day Three Labs.
During the second quarter of 2024, we increased our investment in Day Three Labs and now hold a majority interest in the company with
79% of the shares outstanding and we began reporting consolidated its financial results in January 2024.
For the six months ended January 31, 2024, research
and development expenses were $1.1 million compared to $4.3 million in the year ago period. The year over year reduction is due to the
winding down of early-stage programs, including at Barer Institute.
For the six months ended January 31, 2024, general
and administrative expenses from continuing operations were $4.6 million. For the same period in the prior year, general and administrative
expenses were $5.2 million. The decrease was primarily related to a decrease in non-cash stock-based compensation and payroll expenses.
About Rafael Holdings, Inc.
a holding company with interests in clinical and early-stage pharmaceutical companies, including a majority investment in Cornerstone
Pharmaceuticals, Inc., formerly known as Rafael Pharmaceuticals Inc., a cancer metabolism-based therapeutics company, a majority equity
interest in LipoMedix Pharmaceuticals Ltd., a clinical stage pharmaceutical company, the Barer Institute Inc., a wholly-owned preclinical
cancer metabolism research operation, an investment in Cyclo Therapeutics Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company
dedicated to developing life-changing medicines for patients and families living with challenging diseases through its lead therapeutic
asset, Trappsol Cyclo , a majority investment in Day Three Labs, Inc., a company which reimagines existing cannabis
offerings with pharmaceutical-grade technology and innovation like Unlokt to bring to market better, cleaner, more precise and
predictable products in the cannabis industry, and a majority interest in Rafael Medical Devices, LLC, an orthopedic-focused medical
device company developing instruments to advance minimally invasive surgeries. The Company's primary focus is to expand our investment
portfolio through opportunistic and strategic investments including therapeutics which address high unmet medical needs.
Forward Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters
of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations
surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further
evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements
are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our
actual results, performance or achievements to be materially different from any future results, performance or achievements expressed
or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption "Risk Factors"
in our Annual Report on Form 10-K for the year ended July 31, 2023, and our other filings with the SEC. These factors could cause actual
results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking
statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.
RAFAEL HOLDINGS, INC.
CONSOLIDATED BALANCE SHEETS
thousands, except share and per share data)
| January 31, 2024 | July 31, 2023 | |||||||
| ASSETS | (unaudited) | |||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 7,136 | $ | 21,498 | ||||
| Available-for-sale securities | 64,587 | 57,714 | ||||||
| Interest receivable | 560 | 387 | ||||||
| Convertible note receivable, related party | 1,924 | 1,921 | ||||||
| Accounts receivable, net of allowance for doubtful accounts of $245 at January 31, 2024 and July 31, 2023 | 379 | 213 | ||||||
| Prepaid expenses and other current assets | 487 | 914 | ||||||
| Investment in equity securities | - | 294 | ||||||
| Total current assets | 75,073 | 82,941 | ||||||
| Property and equipment, net | 2,064 | 1,695 | ||||||
| Investments - Other Pharmaceuticals | - | 65 | ||||||
| Investments - Hedge Funds | 2,369 | 4,984 | ||||||
| Investment - Day Three | - | 2,797 | ||||||
| Investments - Cyclo Therapeutics Inc. | 19,567 | 4,763 | ||||||
| Goodwill | 3,571 | - | ||||||
| Intangible assets | 1,888 | - | ||||||
| In-process research and development | 1,575 | 1,575 | ||||||
| Other assets | 42 | 9 | ||||||
| TOTAL ASSETS | $ | 106,149 | $ | 98,829 | ||||
| LIABILITIES AND EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | 509 | $ | 333 | ||||
| Accrued expenses | 845 | 763 | ||||||
| Other current liabilities | 140 | 1,023 | ||||||
| Due to related parties | 69 | 26 | ||||||
| Installment note payable | 1,700 | - | ||||||
| Total current liabilities | 3,263 | 2,145 | ||||||
| Deferred income tax liabilities, net | 545 | - | ||||||
| Other liabilities | 87 | 55 | ||||||
| TOTAL LIABILITIES | $ | 3,895 | $ | 2,200 | ||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| EQUITY | ||||||||
| Class A common stock, $0.01 par value; 35,000,000 shares authorized, 787,163 shares issued and outstanding as of January 31, 2024 and July 31, 2023 | 8 | 8 | ||||||
| Class B common stock, $0.01 par value; 200,000,000 shares authorized, 23,882,117 issued and 23,695,332 outstanding (excluding treasury shares of 101,487) as of January 31, 2024, and 23,708,365 shares issued and 23,490,527 shares outstanding as of July 31, 2023 | 238 | 236 | ||||||
| Additional paid-in capital | 266,159 | 264,010 | ||||||
| Accumulated deficit | (164,924 | ) | (167,333 | ) | ||||
| Treasury stock, at cost; 101,487 and 0 Class B shares as of January 31, 2024 and July 31, 2023, respectively | (168 | ) | - | |||||
| Accumulated other comprehensive loss related to unrealized loss on available-for-sale securities | (88 | ) | (353 | ) | ||||
| Accumulated other comprehensive income related to foreign currency translation adjustment | 3,714 | 3,725 | ||||||
| Total equity | 104,939 | 100,293 | ||||||
| Noncontrolling interests | (2,685 | ) | (3,664 | ) | ||||
| TOTAL EQUITY ATTRIBUTABLE TO RAFAEL HOLDINGS, INC. | 102,254 | 96,629 | ||||||
| TOTAL LIABILITIES AND EQUITY | $ | 106,149 | $ | 98,829 |
RAFAEL HOLDINGS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
thousands, except share and per share data)
| Three Months Ended January 31, | Six Months Ended January 31, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| (unaudited) | (unaudited) | |||||||||||||||
| Revenues | $ | 68 | $ | 70 | $ | 136 | $ | 140 | ||||||||
| G&A Expenses | 2,561 | 2,085 | 4,601 | 5,194 | ||||||||||||
| R&D Expenses | 612 | 2,225 | 1,101 | 4,306 | ||||||||||||
| Depreciation and amortization | 38 | 19 | 55 | 41 | ||||||||||||
| Operating Loss | (3,143 | ) | (4,259 | ) | (5,621 | ) | (9,401 | ) | ||||||||
| Unrealized gain (loss) on investments - Hedge Funds | 51 | 378 | (115 | ) | 251 | |||||||||||
| Impairment of investments - Other Pharmaceuticals | - | (67 | ) | - | (223 | ) | ||||||||||
| Loss on initial investment in Day Three upon acquisition | (1,633 | ) | - | (1,633 | ) | - | ||||||||||
| Unrealized gain on investments - Cyclo Therapeutics Inc | 9,718 | - | 7,594 | |||||||||||||
| Other, net | 1,117 | 701 | 2,347 | 924 | ||||||||||||
| Income (loss) before incomes taxes from continuing operations | 6,110 | (3,247 | ) | 2,572 | (8,449 | ) | ||||||||||
| Benefit from (provision for) taxes | - | (5 | ) | (6 | ) | (10 | ) | |||||||||
| Equity in loss of Day Three | (206 | ) | - | (422 | ) | - | ||||||||||
| Consolidated net income (loss) from continuing operations | 5,904 | (3,252 | ) | 2,144 | (8,459 | ) | ||||||||||
| Discontinued Operations | ||||||||||||||||
| Loss from discontinued operations related to 520 Property | - | (157 | ) | - | (241 | ) | ||||||||||
| Gain on disposal of 520 Property | - | - | - | 6,784 | ||||||||||||
| (Loss) income from discontinued operations | - | (157 | ) | - | 6,543 | |||||||||||
| Consolidated net income (loss) | 5,904 | (3,409 | ) | 2,144 | (1,916 | ) | ||||||||||
| Net loss attributable to noncontrolling interests | (143 | ) | (159 | ) | (265 | ) | (258 | ) | ||||||||
| Net income (loss) attributable to Rafael Holdings, Inc. | $ | 6,047 | $ | (3,250 | ) | $ | 2,409 | $ | (1,658 | ) | ||||||
| Continuing operations earnings (loss) per share | ||||||||||||||||
| Net income (loss) from continuing operations | $ | 5,904 | $ | (3,252 | ) | $ | 2,144 | $ | (8,459 | ) | ||||||
| Net loss attributable to noncontrolling interests | (143 | ) | (159 | ) | (265 | ) | (258 | ) | ||||||||
| Numerator for income (loss) per share from continuing operations | $ | 6,047 | $ | (3,093 | ) | $ | 2,409 | $ | (8,201 | ) | ||||||
| Discontinued operations earnings (loss) per share | ||||||||||||||||
| Net income (loss) from discontinued operations | $ | - | $ | (157 | ) | $ | - | $ | 6,543 | |||||||
| Earnings (loss) per share - Basic | ||||||||||||||||
| Continuing operations | $ | 0.26 | $ | (0.13 | ) | $ | 0.10 | $ | (0.36 | ) | ||||||
| Discontinued operations | - | (0.01 | ) | - | 0.28 | |||||||||||
| Total basic earnings (loss) per common share | $ | 0.26 | $ | (0.14 | ) | $ | 0.10 | $ | (0.07 | ) | ||||||
| Earnings (loss) per share - Diluted | ||||||||||||||||
| Continuing operations | $ | 0.25 | $ | (0.13 | ) | $ | 0.10 | $ | (0.36 | ) | ||||||
| Discontinued operations | - | (0.01 | ) | - | 0.28 | |||||||||||
| Total diluted earnings (loss) per common share | $ | 0.25 | $ | (0.14 | ) | $ | 0.10 | $ | (0.07 | ) | ||||||
| Weighted average number of shares used in calculation of earnings (loss) per share - basic | 23,642,421 | 23,155,018 | 23,643,660 | 23,085,612 | ||||||||||||
| Weighted average number of shares used in calculation of earnings (loss) per share - diluted | 24,402,069 | 23,155,018 | 24,403,308 | 23,085,612 |